MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, CARL had $45,668K increase in cash & cash equivalents over the period. -$29,619K in free cash flow.

Cash Flow Overview

Change in Cash
$45,668K
Free Cash flow
-$29,619K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from initial public off...
    • Proceeds from issuance of series...
    • Accrued compensation
    • Others
Negative Cash Flow Breakdown
    • Purchase of short-term investmen...
    • Payments for deferred initial pu...
    • Accounts receivable, net
    • Others

Cash Flow
2025-12-31
Net loss
-29,634
Depreciation and amortization
281
Stock-based compensation
1,927
Non-cash interest
206
Loss on remeasurement of warrant liabilities
328
Non-cash lease expense
536
Provision for credit losses
414
Provision for excess and obsolete inventory
1,839
Other non-cash items
-17
Accounts receivable, net
5,010
Inventory
2,689
Prepaid expenses and other assets
2,342
Accounts payable
2,323
Accrued liabilities
627
Accrued compensation
2,490
Lease liabilities
-290
Net cash used in operating activities
-28,977
Purchase of short-term investments
24,000
Purchase of property and equipment
642
Capitalized software costs
715
Payment of initial direct costs related to operating leases
126
Net cash used in investing activities
-25,483
Proceeds from initial public offering, net of underwriting discounts and commissions
93,465
Payments for deferred initial public offering costs
5,411
Proceeds from issuance of series c convertible preferred stock, net of issuance costs
11,919
Proceeds from term loan, net of issuance costs
0
Payment of issuance costs related to term loan modification
50
Proceeds from exercises of stock options
205
Net cash provided by financing activities
100,128
Increase in cash, cash equivalents, and restricted cash
45,668
Cash, cash equivalents, and restricted cash at beginning of the period
40,225
Cash, cash equivalents, and restricted cash at end of the period
85,893
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from initialpublic offering, net of...$93,465K Proceeds from issuance ofseries c convertible...$11,919K Proceeds from exercisesof stock options$205K Net cash provided byfinancing activities$100,128K Canceled cashflow$5,461K Increase in cash, cashequivalents, and restricted...$45,668K Canceled cashflow$54,460K Payments for deferredinitial public offering...$5,411K Payment of issuancecosts related to term...$50K Accrued compensation$2,490K Accounts payable$2,323K Stock-based compensation$1,927K Provision for excess andobsolete inventory$1,839K Accrued liabilities$627K Non-cash lease expense$536K Provision for creditlosses$414K Loss onremeasurement of warrant...$328K Depreciation andamortization$281K Non-cash interest$206K Other non-cash items-$17K Net cash used inoperating activities-$28,977K Net cash used ininvesting activities-$25,483K Canceled cashflow$10,988K Net loss-$29,634K Purchase of short-terminvestments$24,000K Capitalized software costs$715K Purchase of property andequipment$642K Payment of initialdirect costs related to...$126K Accounts receivable, net$5,010K Inventory$2,689K Prepaid expenses andother assets$2,342K Lease liabilities-$290K

CARLSMED, INC. (CARL)

CARLSMED, INC. (CARL)